Sumitomo Mitsui Trust Group
LAB icon

Sumitomo Mitsui Trust Group’s Standard BioTools LAB Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$252K Sell
339,600
-72,688
-18% -$55.8K ﹤0.01% 1026
2026
Q2 		$339K Sell
412,288
-30,496
-7% -$28.8K ﹤0.01% 1018
2026
Q1 		$407K Sell
442,784
-3,893,103
-90% -$4.71M ﹤0.01% 960
2025
Q4 		$5.55M Sell
4,335,887
-1,055,942
-20% -$1.42M ﹤0.01% 723
2025
Q3 		$7.01M Sell
5,391,829
-773,708
-13% -$1.01M ﹤0.01% 707
2025
Q2 		$7.4M Sell
6,165,537
-68,156
-1% -$75.6K ﹤0.01% 691
2025
Q1 		$6.73M Sell
6,233,693
-384,701
-6% -$540K ﹤0.01% 715
2024
Q4 		$11.6M Sell
6,618,394
-2,960,169
-31% -$5.51M 0.01% 696
2024
Q3 		$18.5M Sell
9,578,563
-1,063,708
-10% -$2.08M 0.01% 657
2024
Q2 		$18.8M Buy
10,642,271
+1,788,780
+20% +$4.37M 0.01% 643
2024
Q1 		$24M Buy
+8,853,491
New +$21.4M 0.02% 677

Other funds holding LAB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Hollow Brook Wealth Management
Hollow Brook Wealth Management Katonah, New York $575M AUM 19.16% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 29.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group's LAB Position: Q3 2026 in Review

Sumitomo Mitsui Trust Group reduced its Standard BioTools (LAB) stake by 18% in Q3 2026, selling an estimated $55.8K and leaving 339,600 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

Sumitomo Mitsui Trust Group first reported a position in LAB in Q1 2024 and has held it in 11 quarters since. The position peaked at $24M in Q1 2024. 66 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

  • Sumitomo Mitsui Trust Group held 339,600 shares of Standard BioTools worth $252K as of Q3 2026.
  • Sumitomo Mitsui Trust Group sold 72,688 Standard BioTools shares in Q3 2026, an estimated $55.8K.
  • Standard BioTools made up ﹤0.01% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #1026 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Standard BioTools in Q1 2024 and has held it in 11 quarters since.
  • Sumitomo Mitsui Trust Group's Standard BioTools position peaked at $24M in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.